Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma.

Haematologica

Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg.

Published: January 2025

Not available.

Download full-text PDF	Source
http://dx.doi.org/10.3324/haematol.2024.286347	DOI Listing

Publication Analysis

pre-phase treatment

treatment rituximab

rituximab high-dose

high-dose methotrexate

methotrexate re-evaluate

re-evaluate eligibility

eligibility intensive

intensive induction

induction treatment

treatment frail

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!